EUVIMEDEUVIMED entdecken
Crossref

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Xiang Guan, Yinshu Luo, Guoqiang Yang, Jiangwei Chen, Feifei Wang, Qingguo Li, Mingfei Pan, Ning Gu

Soft Science · 19.11.2026 · 6 (4)

DOI: 10.20517/ss.2026.187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Soft Science, online erschienen am 19.11.2026. Verfasst von Xiang Guan und 7 weiteren Autor:innen. Die Arbeit nennt 72 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases (CVDs) remain the leading cause of death and disability worldwide, with atherosclerotic cardiovascular disease (ASCVD) accounting for the largest proportion. Vascular inflammation is a major driver of ASCVD, contributing to plaque formation, progression, and rupture and influencing myocardial repair after infarction. Conventional anti-inflammatory therapies are limited by systemic toxicity and insufficient drug accumulation at lesion sites, restricting their capacity for precise intervention. Nanomedicines can deliver therapeutics to lesion sites and release them in response to local stimuli, potentially reducing systemic toxicity and offering a promising approach to inflammation-targeted treatment of ASCVD. Existing studies have largely cataloged nanocarrier types or evaluated efficacy in isolated disease models but have not provided an integrated perspective on inflammation management across the full ASCVD continuum. This review discusses the role of nanomedicines in preventive plaque stabilization and post-interventional management, including recovery after myocardial infarction and prevention of in-stent restenosis. Preclinical studies indicate that nanomedicines can reduce atherosclerotic plaque size and infarct size and mitigate ischemia-reperfusion injury and stent intimal hyperplasia, potentially improving cardiovascular outcomes. Future work should prioritize mechanistic validation in clinically relevant models and artificial intelligence (AI)-assisted precision medicine to accelerate the safe clinical adoption of inflammation-targeted nanomedicines for CVDs.

Zitieren

APA

Guan, X., Luo, Y., Yang, G., Chen, J., Wang, F., Li, Q., Pan, M., & Gu, N. (2026). Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management. Soft Science, 6(4). https://doi.org/10.20517/ss.2026.187

Vancouver

Guan X, Luo Y, Yang G, Chen J, Wang F, Li Q, et al. Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management. Soft Science. 2026;6(4). doi:10.20517/ss.2026.187

BibTeX
@article{Guan2026,
  author = {Guan, Xiang and Luo, Yinshu and Yang, Guoqiang and Chen, Jiangwei and Wang, Feifei and Li, Qingguo and Pan, Mingfei and Gu, Ning},
  title = {Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management},
  journal = {Soft Science},
  year = {2026},
  volume = {6},
  number = {4},
  doi = {10.20517/ss.2026.187}
}
Kostenlos starten →